Promis Neuroscie Stock Price, News & Analysis

ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has secured $12 million in total financing through two components: a $3 million private placement of warrants and $9 million from the exercise of existing warrants.

The new warrants were sold at $0.1875 per share through a PIPE financing, with an exercise price of $1.25 and a five-year expiration term. The financing, expected to close on July 29, 2025, includes participation from existing investors like Ally Bridge Group. Proceeds will support the clinical development of PMN310, the company's lead therapeutic candidate, and general corporate expenses.

ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has secured total financing of $9.2 million through multiple channels. This includes a $2.4 million private placement through warrant sales at $0.1875 per share, $6.8 million from existing warrant exercises, and $0.8 million from a registered offering.

The new warrants have an exercise price of $1.25 per share with a five-year expiration term. The private placement, expected to close on July 24, 2025, received support from an existing healthcare-focused institutional investor. Funds will support the clinical development of PMN310, the company's lead therapeutic candidate, and general corporate expenses.

ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has announced a $0.8 million registered direct offering through the sale of pre-funded warrants. The company will issue 984,736 pre-funded warrants at $0.8124 per share to an existing healthcare-focused institutional investor.

The warrants will have a nominal exercise price of $0.0001 per share and will be immediately exercisable. The offering is expected to close around July 24, 2025. Proceeds will support the clinical development of PMN310, the company's lead therapeutic candidate, and provide working capital for general corporate expenses.

ProMIS Neurosciences (NASDAQ: PMN) has received Fast Track designation from the FDA for PMN310, its lead therapeutic candidate for Alzheimer's disease treatment. This designation accelerates development for therapies addressing serious unmet medical needs and enables enhanced FDA engagement.

PMN310 is designed to selectively target toxic forms of amyloid-beta, potentially offering reduced side effects compared to current treatments, particularly regarding ARIA (brain swelling and bleeding). The company is currently conducting the PRECISE-AD Phase 1b trial, with interim data expected in Q2 2026 and final results in Q4 2026.

ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech firm focused on developing therapeutic antibodies for neurodegenerative diseases, announced its CEO Neil Warma will participate in a fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. The presentation is scheduled for June 17th, 2025, at 7:00 a.m. ET. The company specializes in treatments for conditions like Alzheimer's Disease, ALS, and multiple system atrophy, targeting toxic oligomers associated with these diseases. Interested parties can access the webcast through the Events page on ProMIS's website, where it will remain available for at least 30 days.

ProMIS Neurosciences (PMN) reported Q1 2025 financial results and significant progress in its clinical programs. The company's lead program, PMN310 for Alzheimer's disease, completed enrollment of its first cohort in the PRECISE-AD trial. The trial will evaluate multiple doses (5, 10, 20 mg/kg) across 128 patients at 22 U.S. sites. Six-month interim results are expected in 1H 2026, with topline results by end-2026. The company's cash position stood at $8.4M as of March 31, 2025, down from $13.3M in December 2024. Q1 2025 saw increased R&D expenses of $5.5M (vs $2.1M in Q1 2024) due to clinical trial costs. Net loss widened to $7.3M (vs $3.6M in Q1 2024). PMN310 targets toxic amyloid-beta oligomers and potentially offers improved safety by avoiding ARIA (Amyloid-Related Imaging Abnormalities), a serious concern with existing therapies. The company also advanced its ALS program (PMN267) and synucleinopathies vaccine program (PMN440) with promising preclinical data.

ProMIS Neurosciences (Nasdaq: PMN) reported its 2024 financial results and key developments. The company successfully initiated a 100-patient Phase 1b clinical trial for PMN310, their lead antibody candidate for Alzheimer's disease. The PRECISE-AD trial is currently enrolling and dosing patients across 22 US sites, with interim results expected in 1H 2026 and topline results by end of 2026.

Financial highlights include cash position of $13.3 million as of December 31, 2024, and completion of a PIPE financing providing $30.3 million upfront with potential for additional $92.4 million from warrant exercises. The company reported net income of $2.8 million for 2024, primarily due to a $22.6 million gain from warrant liability changes. R&D expenses increased to $10.6 million, while G&A expenses slightly decreased to $6.2 million.

The company expanded its IP portfolio with 23 newly granted patents, including 17 for PMN310. They also advanced programs in ALS and Parkinson's disease, identifying PMN440 as a lead vaccine candidate for multiple synucleopathies.

ProMIS Neurosciences (Nasdaq: PMN) announced plans to present preclinical data at the 2025 AD/PD International Conference in Vienna. The company will showcase three key presentations focusing on their platform-derived antibodies and vaccines for neurodegenerative diseases.

The presentations include: (1) A study on Alzheimer's vaccine design showing that immunization with peptide 301 produced maximal reactivity against AD brain oligomers; (2) Research on alpha-synuclein vaccine optimization for treating conditions like Parkinson's disease, demonstrating high-affinity antibodies with selectivity for pathogenic ASyn; and (3) Development of selective antibodies targeting misfolded TDP-43 for treating ALS, frontotemporal dementia, and AD.

The virtual oral presentations will be available on demand starting April 1, 2025, at 7:00am CET.

ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on computationally-derived vaccines for neurodegenerative diseases at the American Academy of Neurology Annual Meeting (April 5-9, 2025) in San Diego.

The company will showcase two key presentations: First, a study on Alzheimer's vaccine optimization showing that immunization with peptide 301 produced maximal reactivity against AD brain oligomers. Second, research on a vaccine for synucleinopathies demonstrating that vaccination with conformational B cell epitopes generated high-affinity antibodies selective for pathogenic alpha-synuclein.

The research focuses on targeting toxic misfolded proteins in conditions like Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company's approach aims to develop vaccines that specifically target toxic amyloid-beta oligomers for AD and pathogenic species of alpha-synuclein for MSA and other synucleinopathies.